Mass tort lawsuit · Checked on November 3, 2026
Ozempic vision loss lawsuit (NAION): status November 2026
Yes, the Ozempic vision loss lawsuit is active. A separate federal MDL, number 3163, had 278 pending lawsuits on November 2, 2026. Plaintiffs allege that semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) caused NAION, a sudden loss of vision from reduced blood flow to the optic nerve. The case is at an early stage.
| Case | MDL 3163 |
|---|---|
| Court | U.S. District Court, Eastern District of Pennsylvania |
| Judge | Karen S. Marston |
| Pending cases | 278 (as of November 2, 2026) |
| Stage | Early stage; MDL created December 2025 |
| New cases | Law firms are filing new cases |
| Next scheduled date | None announced in the records we checked |
| Last checked | November 3, 2026 |
What plaintiffs allege
Plaintiffs allege that the makers of semaglutide and tirzepatide failed to warn of a risk of non-arteritic anterior ischemic optic neuropathy (NAION). The companies deny the claims.
Where the case stands
- The MDL was created in December 2025 and is before Judge Karen S. Marston, who also handles the GLP-1 stomach injury MDL (verified, JPML report; creation date reported).
- European (June 2025) and UK (February 2026) regulators listed NAION as a very rare side effect of semaglutide (reported).
- No trial dates have been set (reported).
Settlement status
No settlement had been announced as of November 3, 2026. We report a settlement only when a court order, a company filing or a company statement confirms it, and we never estimate payment amounts.
Updates
Newest first. Each entry says whether we read the record ourselves (verified) or it comes from coverage (reported).
- November 2026: The federal panel's report of November 2, 2026 listed 278 pending cases (verified, JPML report).
- October 2026: The federal panel's report of October 1, 2026 listed 247 pending cases (verified, JPML report).
- February 2026: The UK regulator listed NAION as a very rare side effect of semaglutide (reported).
- December 2025: The federal panel created MDL 3163 for NAION vision loss cases (reported).
What law firms commonly ask callers
Law firms reviewing these cases usually ask about the following. This is general information, not an assessment of any claim:
- which drug was used and when it started
- whether an eye doctor diagnosed NAION or ischemic optic neuropathy
- the date vision loss began
- eye exam and imaging records
Questions
Is the Ozempic vision loss lawsuit real?
Yes. The U.S. Judicial Panel on Multidistrict Litigation listed 278 pending cases in MDL 3163 as of November 2, 2026 (verified). A pending case is a claim filed in court, not a finding that the claim is true.
When will the Ozempic vision loss lawsuit settle?
Nobody can predict when or whether a mass tort will settle. What has been disclosed so far: No settlement had been announced as of November 3, 2026. We report a settlement only when a court order, a company filing or a company statement confirms it, and we never estimate payment amounts.
Can Ozempic cause vision loss?
European (June 2025) and UK (February 2026) regulators listed NAION as a very rare side effect of semaglutide (reported). Whether the drug caused a particular person's vision loss is what the lawsuits dispute. For medical questions, talk to your doctor.
What is NAION?
Non-arteritic anterior ischemic optic neuropathy is damage to the optic nerve from reduced blood flow. It usually causes sudden, painless vision loss in one eye.
Sources
- JPML, Pending MDL Dockets by Actions Pending, November 2, 2026 verified
- UK MHRA drug safety update on semaglutide and NAION reported
- HarrisMartin on the JPML order centralizing NAION cases reported
Verified means we read the court, agency or company record ourselves on the check date. Reported means the fact comes from news or law firm coverage and could not be confirmed on a primary record.